Island Pharmaceuticals Appoints Sofgen for one-off supply of ISLA-101
- Island Pharmaceuticals (ILA) executes a one-off proposal with Sofgen for the manufacture of ISLA-101 for the upcoming Phase 2a PEACH clinical trial in dengue infected subjects
- The new proposal contains a schedule that has ISLA-101 clinical material being manufactured in mid-August, a six-week delay from most recent estimates
- The company was looking for alternative manufacturers after its prior manufacturer was unable to provide certainty required to plan effectively
- The new timeline has been consolidated and the company expects the investigational new drug (IND) application to be filed in October with the trial commencing in November
- Shares in Island Pharmaceuticals are down 18.8 per cent, trading at 13 cents as of 12:01 pm AEST
